Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Jayasundera

Cardiovascular Disease New York, NY Medical Doctor

NPI 1811908205 CMS profile 354861

148 E 38Th St, New York, NY 10016

Open in the dashboard

General payments

$87,195

286 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Jayasundera of New York, NY is reported in the CMS Open Payments database as having received $87,195 across 286 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $605 22
2024 General $2,362 14
2023 General $9,057 35
2022 General $15,345 43
2021 General $36,505 72
2020 General $16,287 48
2019 General $7,034 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Jayasundera
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Timothy Jayasundera were reported at $605. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Timothy Jayasundera Cardiovascular Disease median Middle half National median
2019 $7,034 $450 $127–$1,392 $163
2020 $16,287 $242 $77–$751 $114
2021 $36,505 $335 $101–$1,037 $132
2022 $15,345 $395 $121–$1,211 $149
2023 $9,057 $443 $136–$1,283 $160
2024 $2,362 $450 $136–$1,323 $164
2025 $605 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $43,218 135 payments
  2. Esperion Therapeutics, Inc. $38,768 46 payments
  3. Amgen Inc. $2,760 9 payments
  4. Boston Scientific Corporation $486 22 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $187 9 payments
  6. HeartFlow, Inc. $178 2 payments
  7. Abbott Laboratories $170 3 payments
  8. Abiomed $167 1 payment
  9. Actelion Pharmaceuticals US, Inc. $151 6 payments
  10. E.R. Squibb & Sons, L.L.C. $138 7 payments
  11. Other $970 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $74,850 43 payments
  2. Food and Beverage $8,573 223 payments
  3. Travel and Lodging $3,744 17 payments
  4. Education $28 3 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $42,332 97 payments
  2. NEXLETOL $38,768 46 payments
  3. NEXLIZET $38,274 33 payments
  4. Repatha $2,725 7 payments
  5. BRILINTA $509 23 payments
  6. WAINUA $190 4 payments
  7. Kerendia $187 9 payments
  8. Synergy $180 8 payments
  9. FFRct $178 2 payments
  10. Impella $167 1 payment
  11. Other $2,422 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 84 drugs

Part D claims

7,265

Median for Cardiology: 2,533

Drug cost

$954,817

Median for Cardiology: $485,213

Branded share of claims

20.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 139 $176,276
Brilinta Ticagrelor Brand 117 $130,174
Eliquis Apixaban Brand 68 $92,552
Januvia Sitagliptin Phosphate Brand 74 $88,742
Xarelto Rivaroxaban Brand 68 $81,925
Entresto Sacubitril/Valsartan Brand 48 $72,261
Trulicity Dulaglutide Brand 12 $33,173
Janumet Sitagliptin Phos/Metformin Hcl Brand 29 $33,018
Tradjenta Linagliptin Brand 20 $27,012
Jardiance Empagliflozin Brand 23 $26,184

The 10 drugs with the highest cost, of 84 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$362,249

Medicare's payments for the services billed

Medicare patients

302

Average age 74

Services billed

3,812

179 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Ischemic heart disease 69%
Arthritis 31%
Chronic kidney disease 17%
Cancer 15%
Atrial fibrillation 10%
Heart failure 8%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $1,994
$1,994 139 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $149
$149 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $32
$32 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $32
$32 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

286 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record